NEW YORK (360Dx) – Cell-based diagnostics firm Celcuity reported after the close of the market on Thursday that its fourth quarter net losses widened year over year.

For the three months ended Dec. 31, 2017 Celcuity posted a net loss of $1.7 million, or $.17 per share, compared to a net loss of $902,434, or $.14 per share, in the year-ago period. The firm's adjusted loss per share for Q4 2017 was $.14.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.